CYTK Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 6% planned / 94% discretionary
Largest single sale: $6.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Blum Robert I | President & CEO | Sell | 7,500 | $65.46 | $491.0K | 278,544 −2.6% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $68.29 | $239.0K | 153,902 −2.2% of holding | |
| Blum Robert I | President & CEO | Sell | 97,926 | $69.33 | $6.8M | None left | |
| Landry Robert E | Director | Sell | 1,000 | $72.13 | $72.1K | 8,184 −10.9% of holding | |
| Blum Robert I | President & CEO | Sell 10b5-1 | 7,500 | $73.44 | $550.8K | 377,820 −1.9% of holding | |
| Landry Robert E | Director | Sell | 1,000 | $74.66 | $74.7K | 9,184 −9.8% of holding | |
| Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | $75.46 | $264.1K | 153,902 −2.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.